Calcium kinetics in children with osteogenesis imperfecta type III and IV: pre- and post-growth hormone therapy

Area of Science:

• Biochemistry
• Pediatrics
• Endocrinology

Background:

• Osteogenesis imperfecta (OI) is a genetic disorder characterized by brittle bones.
• Growth hormone (GH) therapy is used in some pediatric conditions to improve linear growth.
• Calcium (Ca) metabolism and bone binding are crucial for skeletal development.

Purpose of the Study:

• To investigate the effects of GH treatment on calcium (Ca) kinetics in children with osteogenesis imperfecta (OI) types III and IV.
• To analyze Ca binding to bone using a stable isotope technique and a binding site model.
• To correlate changes in Ca binding with growth rate in response to GH therapy.

Main Methods:

• Utilized a (42)Ca stable isotope technique to study serum Ca dilution kinetics.
• Administered GH therapy for 1-1.5 years to pediatric patients with OI types III and IV.
• Analyzed kinetic data using a binding site model describing reversible and irreversible Ca binding to bone.
• Measured isotopic enrichments of (42)Ca over 7 days via thermal ionization mass spectrometry.

Main Results:

• GH treatment increased short-term Ca binding sites (theta) and the half-life of Ca on long-term binding sites in OI type III patients.
• OI type III patients exhibited a trend toward increased growth rate with improved Ca binding and a 75% growth rate increase in the first 6 months.
• GH treatment increased Ca ion half-life on long-term binding sites in OI type IV patients, but without a significant correlation to growth rate.

Conclusions:

• GH treatment significantly alters Ca binding kinetics in the bone of children with OI type III.
• Enhanced Ca binding to bone may play a role in promoting growth in OI type III patients.
• The effects of GH on Ca metabolism and growth differ between OI types III and IV.